Baseline platelet aggregation and major receptor expression predict subsequent activity following thrombolysis for acute myocardial infarction

Scand Cardiovasc J. 2000;34(1):53-8. doi: 10.1080/14017430050142404.

Abstract

The early identification of patients with heightened platelet activity for aggressive antiplatelet regimens represents a critical clinical issue in acute myocardial infarction (AMI) therapy. We sought to determine whether the degree of pre-reperfusion platelet function is related to subsequent activity following thrombolysis. Platelets were investigated at baseline and at 24 h following thrombolytic therapy by aggregometry, and flow cytometry in 19 AMI patients enrolled in the GUSTO-III trial. Regression analysis revealed a significant correlation for 5 microM ADP (r2 = 0.529), 10 microM ADP (r2 = 0.445), thrombin (r2 = 0.226), collagen (r2 = 0.568), and ristocetin-induced aggregation (r2 = 0.964). Platelet expression linearly correlated for GPIIb/IIIa (r2 = 0.337), P-selectin (r = 0.817), PECAM-1 (r2 = 0.586), and the vitronectin receptor (r2 = 0.634). The data suggest that the baseline characteristics predict future platelet activity, and may prospectively identify patients who will benefit most from antiplatelet strategies after coronary thrombolysis.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase III
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers / blood
  • Blood Platelets / drug effects
  • Blood Platelets / physiology*
  • Female
  • Flow Cytometry
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction / blood
  • Myocardial Infarction / drug therapy*
  • P-Selectin / blood
  • P-Selectin / drug effects
  • Pilot Projects
  • Platelet Aggregation / drug effects
  • Platelet Aggregation / physiology*
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Platelet Count
  • Platelet Endothelial Cell Adhesion Molecule-1 / blood*
  • Platelet Endothelial Cell Adhesion Molecule-1 / drug effects
  • Platelet Glycoprotein GPIIb-IIIa Complex / drug effects
  • Platelet Glycoprotein GPIIb-IIIa Complex / metabolism
  • Platelet Membrane Glycoproteins / drug effects
  • Platelet Membrane Glycoproteins / metabolism*
  • Prognosis
  • Prospective Studies
  • Receptors, Vitronectin / blood*
  • Receptors, Vitronectin / drug effects
  • Thrombolytic Therapy*

Substances

  • Biomarkers
  • P-Selectin
  • Platelet Aggregation Inhibitors
  • Platelet Endothelial Cell Adhesion Molecule-1
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Platelet Membrane Glycoproteins
  • Receptors, Vitronectin